Gene variants affecting bioavailability of drugs: Towards individualized immunosuppressive therapy?

Journal of the American Society of Nephrology

Volumn 14, Issue 7, 2003, Pages 1955-1957

  Schröppel, Bernd ^a   Murphy, Barbara ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; AZATHIOPRINE; GLYCOPROTEIN P; MICROSATELLITE DNA; MULTIDRUG RESISTANCE PROTEIN 1; TACROLIMUS; THIOPURINE METHYLTRANSFERASE;

ALLELE; BLOOD TOXICITY; CLINICAL TRIAL; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG RESPONSE; EDITORIAL; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN GENOME; IMMUNOSUPPRESSIVE TREATMENT; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN FUNCTION; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 0038544550     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000077400.34445.CF     Document Type: Editorial

References (28)

1. Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G, Sherry S, Mullikin JC, Mortimore BJ, Willey DL, Hunt SE, Cole CG, Coggill PC, Rice CM, Ning Z, Rogers J, Bentley DR, Kwok PY, Mardis ER, Yeh RT, Schultz B, Cook L, Davenport R, Dante M, Fulton L, Hillier L, Waterston RH, McPherson JD, Gilman B, Schaffner S, Van Etten WJ, Reich D, Higgins J, Daly MJ, Blumenstiel B, Baldwin J, Stange-Thomann N, Zody MC, Linton L, Lander ES, Altshuler D: A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409: 928-933, 2001
2. Evans WE, Relling MV: Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 286: 487-491, 1999
3. Danesi R, Mosca M, Boggi U, Mosca F, Del Tacca M: Genetics of drug response to immunosuppressive treatment and prospects for personalized therapy. Mol Med Today 6: 475-482, 2000
4. Evans WE, McLeod HL: Pharmacogenomics - Drug disposition, drug targets, and side effects. N Engl J Med 348: 538-549, 2003
5. Black AJ, McLeod HL, Capell HA, Powrie RH, Matowe LK, Pritchard SC, Collie-Duguid ES, Reid DM: Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 129: 716-718, 1998
6. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS: A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 63: 977-983, 1997
7. Borst P, Evers R, Kool M, Wijnholds J: A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92: 1295-1302, 2000
8. Anglicheau D, Verstuyft C, Laurent-Puig P, Becquemont L, Schalageter H, cassinat B, Beaune P, Legendre C, Thervet E: Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. Journal Amer Soc Neph 1889-1896, 2003
9. Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, Bowman P, Boyle G, Law Y, Miller S, Lamba J, Burckart GJ: Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 3: 477-483, 2003
10. Fromm MF: The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev 54: 1295-1310, 2002
11. Goldstein DB: Islands of linkage disequilibrium. Nat Genet 29: 109-111, 2001
12. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR: Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38: 1277-1287, 1990
13. Marder B, Schröppel B, Murphy B: Genetic variability and transplantation. Curr Opin Urol 13: 81-89, 2003
14. Fischereder M, Luckow B, Hocher B, Wuthrich RP, Rothenpieler U, Schneeberger H, Panzer U, Stahl RA, Hauser IA, Budde K, Neumayer H, Kramer BK, Land W, Schlöndorff D: CC chemokine receptor 5 and renal-transplant survival. Lancet 357: 1758-1761, 2001
15. Asano H, Kobayashi T, Uchida K, Hayashi S, Yokoyama I, Inoko H, Takagi H: Significance of tumor necrosis factor microsatellite polymorphism in renal transplantation. Tissue Antigens 50: 484-488, 1997
16. Hahn AB, Kasten-Jolly JC, Constantino DM, Graffunder E, Singh TP, Shen GK, Conti DJ: TNF-alpha, IL-6, IFN-gamma, and IL-10 gene expression polymorphisms and the IL-4 receptor alpha-chain variant Q576R: Effects on renal allograft outcome. Transplantation 72: 660-665, 2001
17. Pelletier R, Pravica V, Perrey C, Xia D, Ferguson RM, Hutchinson I, Orosz C: Evidence for a genetic predisposition towards acute rejection after kidney and simultaneous kidney-pancreas transplantation. Transplantation 70: 674-680, 2000
18. Poli F, Boschiero L, Giannoni F, Tonini M, Scalamogna M, Ancona G, Sirchia G: Tumour necrosis factor-alpha gene polymorphism: Implications in kidney transplantation. Cytokine 12: 1778-1783, 2000
19. Sankaran D, Asderakis A, Ashraf S, Roberts IS, Short CD, Dyer PA, Sinnott PJ, Hutchinson IV: Cytokine gene polymorphisms predict acute graft rejection following renal transplantation. Kidney Int 56: 281-288, 1999
20. Hutchings A, Guay-Woodford L, Thomas JM, Young CJ, Purcell WM, Pravica V, Perrey C, Hutchinson IV, Benfield MR: Association of cytokine single nucleotide polymorphisms with B7 costimulatory molecules in kidney allograft recipients. Pediatr Transplant 6: 69-77, 2002
21. Poole KL, Gibbs PJ, Evans PR, Sadek SA, Howell WM: Influence of patient and donor cytokine genotypes on renal allograft rejection: evidence from a single centre study. Transpl Immunol 8: 259-265, 2001
22. Hackstein H, Kluter H, Fricke L, Hoyer J, Bein G: The IL-4 receptor alpha-chain variant Q576R is strongly associated with decreased kidney allograft survival. Tissue Antigens 54: 471-477, 1999
23. Marshall SE, McLaren AJ, McKinney EF, Bird TG, Haldar NA, Bunce M, Morris PJ, Welsh KI: Donor cytokine genotype influences the development of acute rejection after renal transplantation. Transplantation 71: 469-476, 2001
24. Muller-Steinhardt M, Hartel C, Muller B, Kirchner H, Fricke L: The interleukin-6-174promoter polymorphism is associated with long-term kidney allograft survival. Kidney Int 62: 1824-1827, 2002
25. Abdi R, Tran TB, Sahagun-Ruiz A, Murphy PM, Brenner BM, Milford EL, McDermott DH: Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation. J Am Soc Nephrol 13: 754-758, 2002
26. Kruger B, Schröppel B, Ashkan R, Marder B, Zulke C, Murphy B, Kramer BK, Fischereder M A Monocyte chemoattractant protein-1 (MCP-1) polymorphism and outcome after renal transplantation. J Am Soc Nephrol 13: 2585-2589, 2002
27. McLaren AJ, Marshall SE, Haldar NA, Mullighan CG, Fuggle SV, Morris PJ, Welsh KI: Adhesion molecule polymorphisms in chronic renal allograft failure. Kidney Int 55: 1977-1982, 1999
28. Slavcheva E, Albanis E, Jiao Q, Tran H, Bodian C, Knight R, Milford E, Schiano T, Tomer Y, Murphy B: Cytotoxic T-lymphocyte antigen 4 gene polymorphisms and susceptibility to acute allograft rejection. Transplantation 72: 935-940, 2001